Tumor Microenvironment‐Driven Structural Transformation of Vanadium‐Based MXenzymes to Amplify Oxidative Stress for Multimodal Tumor Therapy
Advanced Science,
Год журнала:
2025,
Номер
unknown
Опубликована: Янв. 23, 2025
MXenzymes,
a
promising
class
of
catalytic
therapeutic
material,
offer
great
potential
for
tumor
treatment,
but
they
encounter
significant
obstacles
due
to
suboptimal
efficiency
and
kinetics
in
the
microenvironment
(TME).
Herein,
this
study
draws
inspiration
from
electronic
structure
transition
metal
vanadium,
proposing
leverage
TME
specific-features
induce
structural
transformations
sheet-like
vanadium
carbide
MXenzymes
(TVMz).
These
trigger
cascading
reactions
that
amplify
oxidative
stress,
thereby
significantly
enhancing
multimodal
therapy.
Specifically,
engineered
HTVMz,
coated
with
hyaluronic
acid,
exhibits
good
stability
generates
thermal
effect
under
NIR-II
laser
irradiation.
The
effect,
combined
characteristics,
facilities
transformation
into
ultra-small
oxide
nanozymes
(VOx).
enlarged
surface
area
VOx
substantially
enhances
ROS
regeneration
amplifies
which
promotes
lysosomal
permeability
induces
endoplasmic
reticulum
stress.
high-valent
interacts
intracellular
glutathione,
disrupting
redox
homeostasis
intensifying
stress
further.
amplifications
accelerate
apoptosis,
ferroptosis,
suppress
HSP90
expression.
Consequently,
heightened
sensitivity
HTVMz
synergistically
cell
death
via
pathways.
This
presents
an
innovative
strategy
therapy
by
manipulating
structures,
advancing
field
Язык: Английский
ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Сен. 5, 2024
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
has
revolutionized
the
treatment
of
hematologic
malignancies,
offering
remarkable
remission
rates
in
otherwise
refractory
conditions.
However,
its
expansion
into
broader
oncological
applications
faces
significant
hurdles,
including
limited
efficacy
solid
tumors,
safety
concerns
related
to
toxicity,
and
logistical
challenges
manufacturing
scalability.
This
review
critically
examines
latest
advancements
aimed
at
overcoming
these
obstacles,
highlighting
innovations
CAR
engineering,
novel
targeting
strategies,
improvements
delivery
persistence
within
tumor
microenvironment.
We
also
discuss
development
allogeneic
T
cells
as
off-the-shelf
therapies,
strategies
mitigate
adverse
effects,
integration
with
other
therapeutic
modalities.
comprehensive
analysis
underscores
synergistic
potential
enhance
safety,
efficacy,
accessibility
providing
a
forward-looking
perspective
on
their
evolutionary
trajectory
cancer
treatment.
Язык: Английский
EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma
Frontiers in Oncology,
Год журнала:
2024,
Номер
14
Опубликована: Сен. 19, 2024
Glioblastoma
is
the
most
common
primary
brain
tumor.
Although
there
have
been
significant
advances
in
surgical
techniques,
chemo
and
immunotherapies,
radiation
therapy,
outcomes
continue
to
be
devastating
for
these
patients
with
minimal
improvements
survival.
Chimeric
antigen
receptor
T
cell
therapy
a
revolutionary
approach
that
new
pillar
treatment
of
cancer.
CAR
has
produced
remarkable
results
hematological
malignancies;
however,
multiple
limitations
currently
prevent
it
from
being
first-line
especially
solid
tumors.
Epidermal
growth
factor
classically
amplified
glioblastoma,
variant,
EGFR
variant
III,
expressed
on
making
an
exciting
potential
target
therapy.
preclinical
potential,
clinical
data
heterogeneous.
In
this
review,
we
assess
state
field
EGFR-targeted
cells.
Язык: Английский
Nanobody-enhanced chimeric antigen receptor T-cell therapy: overcoming barriers in solid tumors with VHH and VNAR-based constructs
Biomarker Research,
Год журнала:
2025,
Номер
13(1)
Опубликована: Март 11, 2025
Abstract
CAR-T
cells
are
genetically
modified
T
lymphocytes
that
express
chimeric
antigen
receptors
(CAR)
on
their
surfaces.
These
enable
to
recognize
specific
antigens
target
cells,
triggering
a
response
leads
targeted
cytotoxicity.
While
therapy
has
effectively
treated
various
blood
cancers,
it
faces
significant
challenges
in
addressing
solid
tumors.
include
identifying
precise
tumor
antigens,
overcoming
evasion,
and
enhancing
the
function
of
within
microenvironment.
Single
domain
antibody,
versatile
tools
with
low
immunogenicity,
high
stability,
strong
affinity,
show
promise
for
improving
efficacy
against
By
these
challenges,
single
antibody
potential
overcome
limitations
associated
ScFv
antibody-based
therapies.
This
review
highlights
benefits
utilizing
therapy,
particularly
targeting
explores
development
strategies
could
advance
field.
Язык: Английский
Molecular crosstalk between GPCR and receptor tyrosine-protein kinase in neuroblastoma: molecular mechanism and therapeutic implications
Medical Oncology,
Год журнала:
2025,
Номер
42(5)
Опубликована: Март 23, 2025
Язык: Английский
Therapeutic targets of armored chimeric antigen receptor T cells navigating the tumor microenvironment
Experimental Hematology and Oncology,
Год журнала:
2024,
Номер
13(1)
Опубликована: Сен. 30, 2024
Язык: Английский
Unlocking the potential of iPSC-derived immune cells: engineering iNK and iT cells for cutting-edge immunotherapy
Frontiers in Immunology,
Год журнала:
2024,
Номер
15
Опубликована: Авг. 30, 2024
Induced
pluripotent
stem
cells
(iPSCs)
have
emerged
as
a
revolutionary
tool
in
cell
therapies
due
to
their
ability
differentiate
into
various
types,
unlimited
supply,
and
potential
off-the-shelf
products.
New
advances
iPSC-derived
immune
generated
potent
iNK
iT
which
showed
robust
killing
of
cancer
animal
models
clinical
trials.
With
the
advent
advanced
genome
editing
technologies
that
enable
development
highly
engineered
cells,
here
we
outline
12
strategies
engineer
iPSCs
overcome
limitations
challenges
current
cell-based
immunotherapies,
including
safety
switches,
stealth
edits,
avoiding
graft-versus-host
disease
(GvHD),
targeting,
reduced
lymphodepletion,
efficient
differentiation,
increased
Язык: Английский